We report the 3D structure of human 2 adrenergic receptor (AR) predicted by using the MembStruk first principles method. To validate this structure, we use the HierDock first principles method to predict the ligand-binding sites for epinephrine and norepinephrine and for eight other ligands, including agonists and antagonists to 2 AR and ligands not observed to bind to 2 AR. The binding sites agree well with available mutagenesis data, and the calculated relative binding energies correlate reasonably with measured binding affinities. In addition, we find characteristic differences in the predicted binding sites of known agonists and antagonists that allow us to infer the likely activity of other ligands. The predicted ligand-binding properties validate the methods used to predict the 3D structure and function. This validation is a successful step toward applying these procedures to predict the 3D structures and function of the other eight subtypes of ARs, which should enable the development of subtype-specific antagonists and agonists with reduced side effects.T he adrenergic receptors (ARs) are the class of G proteincoupled receptors (GPCR) responsible for mediating the effects of the catecholamines epinephrine and norepinephrine. There are currently nine known human ARs, partitioned into three subclasses: ␣1 (three subtypes located in vascular smooth muscle, the digestive tract, liver, and postsynaptically in the CNS), ␣2 (three subtypes located pre-and postsynaptically in the CNS, and in a wide variety of peripheral sites), and  (three subtypes located primarily in cardiac, vascular, and adipose tissues, respectively).The members of this receptor class mediate a wide variety of physiological responses, including vasodilation and vasoconstriction, heart rate modulation, regulation of lipolysis, and blood clotting. These diverse and important functions make the adrenergic receptors a tempting pharmaceutical target, but attempts to create effective and specific drugs acting on these receptors have been slowed down by the lack of a 3D structure for any GPCR other than the bovine photoreceptor rhodopsin. The focus of this paper is the 2AR, which is targeted by agonist therapy in the treatment of asthma. Unfortunately, 2 agonists also exhibit crossreactivity with the other ARs, causing side effects such as increased heart rate and blood pressure (1). Three-dimensional models of the ARs would be extremely useful in the design of subtype-specific pharmaceutical compounds. In addition, the ARs have been thoroughly studied experimentally so that there are ample data for validating the structural predictions, which may in turn provide improved understanding for the superfamily of GPCRs.We report here the predicted 3D structure of 2AR, which we use to predict detailed binding sites of agonists and antagonists to 2AR. This is an excellent case for validation because there is a wealth of experimental data on ligand-binding sites and mutational analysis with which to compare our results (2, 3).We use the MembStruk ...